Trials / Withdrawn
WithdrawnNCT02897999
Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers
A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Qu Biologics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this dose-escalation study is to assess the safety and pharmacodynamics of single and multiple doses of QBKPN SSI, administered subcutaneously to healthy adult volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | QBKPN | QBKPN Site Specific Immunomodulators |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2016-09-13
- Last updated
- 2017-08-24
Source: ClinicalTrials.gov record NCT02897999. Inclusion in this directory is not an endorsement.